SP-8203
Phase 3Small molecule
SP-8203 is one of 38 small molecule programs targeting Ischemic stroke. It is currently in Phase 3.
1
Indications
4
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
116 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Tnkase
RochePhase 3
Ozempic
Novo NordiskPhase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Butylphthalide
PPeking Union Medical College Hospital
Phase 3
PCSK9 Inhibitor
YYun Dai Chen
Phase 3
Edaravone Dexborneol
SSimcere Pharmaceutical Co., Ltd
Phase 3
SP-8203
SShin Poong Pharmaceutical Co. Ltd.
Phase 3
Tenecteplase or Alteplase
IInsel Gruppe AG, University Hospital Bern
Phase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ischemic stroke3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SP-8203. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details